XERSXeris Biopharma Holdings, Inc.
Who owns XERS
237 institutions reported holding XERS for 2026Q2, together 61% of the company, more than the 228 a quarter earlier.
Institutions reporting a position · as of 2026Q2 · up from 228 the quarter before
- Shares held by institutions
- 108.2M
Shares held by institutions · 61% of the company · long US equity positions only, as reported on Form 13F
- Reported value
- $857M
Reported value · at Jun 30, 2026 prices, not today's
- Top 5 holders
- 24%
Top 5 holders · of the whole company, between five filers
Details›
- Reporting quarter2026-06-30
- 2026Q2
- Quarters on record
- 33
- New positions
- 34
- Positions exited
- 32
- Added to
- 99
- Reduced
- 62
- Top 10 holdersof the company
- 33%
- Shares sold shortsettled Sep 15, 2026
- 8.1M
- Short interestof shares outstanding
- 4.5%
- Days to coverat the average daily volume
- 4.8
- Change in the short positionsince the Aug 31, 2026 count
- +0.22%
| Quarter | Filers | Shares | Reported value |
|---|---|---|---|
| 2026Q2 | 237 | 108.2M | $857M |
| 2026Q1 | 228 | 105.2M | $611M |
| 2025Q4 | 221 | 100.7M | $791M |
| 2025Q3 | 228 | 96.9M | $788M |
| 2025Q2 | 199 | 90.5M | $422M |
| 2025Q1 | 197 | 87.6M | $481M |
| 2024Q4 | 161 | 65.6M | $222M |
| 2024Q3 | 142 | 63.9M | $182M |
| 2024Q2 | 133 | 60.7M | $137M |
| 2024Q1 | 142 | 60.5M | $134M |
| 2023Q4 | 120 | 59.9M | $141M |
| 2023Q3 | 110 | 55.0M | $102M |
| 2023Q2 | 103 | 55.9M | $147M |
| 2023Q1 | 92 | 49.5M | $81M |
| 2022Q4 | 97 | 53.9M | $72M |
| 2022Q3 | 101 | 57.3M | $89M |
| Holder | Shares | % of company | Value |
|---|---|---|---|
| BlackRock Inc. | 14.5M | 8.2% | $115M |
| VANGUARD GROUP INC | 11.4M | 6.4% | $91M |
| D. E. Shaw & Co., INC. | 7.8M | 4.4% | $62M |
| STATE STREET CORP | 4.8M | 2.7% | $38M |
| GEODE CAPITAL MANAGEMENT LLC | 4.7M | 2.7% | $37M |
| Nuveen Asset Management, LLC | 4.4M | 2.5% | $35M |
| Rosalind Advisors, Inc. | 2.9M | 1.6% | $23M |
| Qube Research & Technologies Ltd | 2.9M | 1.6% | $23M |
| WELLINGTON MANAGEMENT GROUP LLP | 2.4M | 1.3% | $19M |
| MORGAN STANLEY | 2.3M | 1.3% | $19M |
| Settlement | Shares short | Of shares outstanding | Days to cover |
|---|---|---|---|
| Sep 15, 2026 | 8.1M | 4.5% | 4.8 |
| Aug 31, 2026 | 8.0M | 4.5% | 5.5 |
| Aug 14, 2026 | 8.7M | 4.9% | 4.4 |
| Jul 31, 2026 | 9.2M | 5.2% | 6.8 |
| Jul 15, 2026 | 10.1M | 5.7% | 4.4 |
| Jun 30, 2026 | 12.8M | 7.2% | 5.4 |
| Jun 15, 2026 | 12.8M | 7.2% | 7.3 |
| May 29, 2026 | 12.5M | 7.0% | 9.4 |
| May 15, 2026 | 12.4M | 7.0% | 5.8 |
| Apr 30, 2026 | 15.9M | 8.9% | 12.7 |
| Apr 15, 2026 | 15.7M | 8.9% | 11.0 |
| Mar 31, 2026 | 16.4M | 9.2% | 8.9 |
SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold. The short position is FINRA's consolidated count for each twice-monthly settlement date, as a share of shares outstanding.
Drug Manufacturers, Specialty & Generic
Ranks #25 of 41 by RyuScore